Immunome, Inc.

NasdaqCM IMNM

Immunome, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -114.51 M

Immunome, Inc. EBIT is USD -114.51 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -404.03% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Immunome, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -22.72 M, a 38.53% change year over year.
Immunome, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -36.96 M, a -72.52% change year over year.
Immunome, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -21.42 M, a -28.93% change year over year.
Immunome, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -16.61 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqCM: IMNM

Immunome, Inc.

CEO	Dr. Clay B. Siegall Ph.D.
IPO Date	Oct. 2, 2020
Location	United States
Headquarters	665 Stockton Drive
Employees	55
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Key trends

Past 5 years